CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY
Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Alberto Bottini(University of Genoa), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Andrea Michelotti(University of Pisa), Gordana Jovic(MRC Clinical Trials Unit at UCL), Luigi Cavanna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Cristina Oliva(Universidad de Huelva)
IRIS UNIMORE (University of Modena and Reggio Emilia)
January 1, 2007
Cited by 4
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830